Yes for endpoints such as overall survival, readouts can take longer when patients are doing well.
But the endpoints they were reporting for cohorts 1 and 2 didnt require waiting extended periods.
Just seems strange they haven't reported them. Maybe if they were poor or mediocre, they are waiting in the hope that they can announce good resulrs for cohort 4 at the same time.
I guess we'll find out at the end of the year or early CY24.
Clinical Trials, page-11
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.951M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $30.25K | 3.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1600735 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 545477 | 5 |
View Market Depth
| Last trade - 15.59pm 15/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |